Skip to main content
    U

    USANA Health Sciences Inc (USNA)

    Official site

    CONSUMER DEFENSIVE • PACKAGED FOODS • NYSE

    $13.55
    +0.31 (+2.34%)

    Market Cap: $244.79M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    USANA Health Sciences Inc (USNA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 3, 2026. Financial statements from company filings, amounts in US dollars.

    USANA Health Sciences reported revenue of $925.26M for the fiscal year ended Dec 31, 2025, up 8.3% from the year before. That year, net income was $10.76M with a net margin of 1.2%, operating cash flow was $22.35M and free cash flow was $8.53M. The quarter ended Sep 30, 2026 had revenue of $205.88M and net income of -$5.56M.

    Revenue and Margins

    The operating margin was 5.5% in the fiscal year ended Dec 2025, the lowest of the 10 years shown. Over the 9 years to Dec 2025, revenue fell from $1.01B, a compound annual decline of 1.0%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$925.26M+8.3%78.3%5.5%1.2%
    Dec 2024$854.50M-7.2%79.4%7.8%4.9%
    Dec 2023$921.01M-7.8%79.4%10.1%6.9%
    Dec 2022$998.60M-15.8%80.6%10.8%6.9%
    Dec 2021$1.19B+4.6%81.6%14.3%9.8%
    Dec 2020$1.13B+7.0%81.6%15.6%11.0%
    Dec 2019$1.06B-10.8%82.3%13.8%9.5%
    Dec 2018$1.19B+13.6%83.1%15.8%10.6%
    Dec 2017$1.05B+4.1%82.9%12.7%6.0%
    Dec 2016$1.01BN/A82.1%13.8%9.9%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income fell 74.4% from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$925.26M$854.50M$921.01M$998.60M$1.19B$1.13B$1.06B$1.19B$1.05B$1.01B
    Cost of revenue$200.85M$175.75M$189.40M$193.89M$217.90M$209.11M$187.50M$200.71M$179.40M$180.19M
    Gross profit$724.40M$678.75M$731.62M$804.71M$968.57M$925.53M$873.40M$988.54M$867.86M$825.89M
    Research and development$0$11.57M$11.45M$11.56M$11.11M$10.63M$10.26M$8.84M$8.95M$8.84M
    Operating income$50.86M$66.32M$93.07M$107.61M$170.19M$176.49M$146.19M$188.35M$132.50M$138.62M
    Net income$10.76M$42.03M$63.79M$69.35M$116.50M$124.66M$100.53M$126.22M$62.53M$100.04M
    EBITDA$82.07M$98.86M$123.11M$129.02M$192.38M$199.00M$169.20M$205.20M$148.61M$152.10M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$205.88M$223.27M$250.22M$226.20M$213.67M$235.85M$249.54M$213.61M$200.22M$212.87M$227.80M$221.08M
    Gross profit$157.17M$174.93M$190.78M$176.79M$164.85M$177.92M$188.75M$171.06M$157.40M$168.72M$181.57M$175.85M
    Operating income-$1.45M-$20.00M$13.87M$17.25M$1.22M$16.72M$15.67M$8.21M$15.60M$17.84M$24.67M$24.22M
    Net income-$5.56M-$21.38M$7.51M-$1.77M-$6.52M$9.65M$9.40M$4.48M$10.61M$10.43M$16.54M$16.77M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $14.00M by $144.38M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$742.91M$748.19M$632.76M$596.55M$577.74M$640.89M$516.93M$554.46M$519.27M$470.64M
    Current assets$288.40M$279.19M$417.75M$381.23M$362.85M$423.21M$327.61M$392.33M$340.16M$277.86M
    Cash and equivalents$158.38M$181.77M$330.42M$288.42M$239.83M$312.88M$234.83M$214.33M$247.13M$175.77M
    Total liabilities$156.64M$161.86M$135.56M$162.08M$182.62M$199.24M$165.22M$163.32M$156.06M$145.35M
    Short-term debt$14.00M$29.01M$8.06M$6.89M$7.08M$8.62M$8.32M$20.77M$17.00M$21.46M
    Shareholder equity$533.10M$532.11M$497.20M$434.47M$395.12M$441.65M$351.71M$391.15M$363.21M$325.29M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$708.47M$703.21M$738.97M$742.91M$726.59M$734.53M$746.60M$748.19M$671.31M$631.42M$629.27M$632.76M
    Total liabilities$138.38M$132.24M$144.18M$156.64M$145.04M$148.97M$162.72M$161.86M$138.22M$119.21M$129.29M$135.56M
    Cash and equivalents$178.91M$168.56M$162.75M$158.38M$145.35M$151.34M$179.61M$181.77M$364.89M$332.42M$328.34M$330.42M
    Shareholder equity$526.76M$526.31M$543.55M$533.10M$528.07M$531.06M$529.76M$532.11M$533.09M$512.21M$499.99M$497.20M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 38.2% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$22.35M$60.99M$70.64M$103.90M$121.23M$160.40M$126.73M$152.12M$123.78M$137.03M
    Capital expenditures$13.82M$10.07M$14.49M$10.40M$12.76M$15.09M$16.57M$11.43M$13.22M$32.70M
    Free cash flow$8.53M$50.92M$56.15M$93.50M$108.46M$145.31M$110.16M$140.69M$110.56M$104.33M
    Investing cash flow-$10.13M-$213.09M-$11.97M-$12.37M-$14.19M-$33.96M$47.49M-$69.00M-$12.90M-$31.88M
    Financing cash flow-$40.60M$9.55M-$14.24M-$30.09M-$181.41M-$59.44M-$152.05M-$105.28M-$50.32M-$64.86M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$11.96M$23.32M$9.76M-$3.39M-$1.96M$12.22M$15.48M$5.79M$29.53M$7.99M$17.68M$26.02M
    Capital expenditures$3.52M$3.15M$2.65M$2.79M$3.20M$5.03M$2.80M$1.80M$2.40M$2.67M$3.20M$7.32M
    Free cash flow$8.44M$20.16M$7.11M-$6.18M-$5.16M$7.19M$12.68M$3.98M$27.14M$5.32M$14.48M$18.70M
    Last 12 quarters

    Frequently Asked Questions About USNA

    What is USANA Health Sciences' annual revenue?

    USANA Health Sciences reported revenue of $925.26M for the fiscal year ended Dec 31, 2025.

    How fast is USANA Health Sciences' revenue growing?

    Revenue was up 8.3% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -2.5%.

    Is USANA Health Sciences profitable?

    Yes. USANA Health Sciences reported net income of $10.76M for the fiscal year ended Dec 31, 2025, with a net margin of 1.2%.

    How much free cash flow does USNA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $22.35M minus capital expenditures of $13.82M produced free cash flow of $8.53M.

    How much debt does USANA Health Sciences have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $14.00M and cash and equivalents of $158.38M.